|
Contract Research organisations
An Outlook
Financial performance of large innovative pharmaceutical companies in 2010 indicated a gloomy prospect for these well-established leaders in their domain. This trend is expected to grow as many drugs are going off-patent in time to come, and with very few blockbusters drugs entering to market due to strict FDA regulations. For instance, Pfizer, stands to lose huge revenue when its patent on Lipitor, the blockbuster cholesterol drug, expires. This will impact the sales and profit of these companies. Interestingly, these changes are giving opportunities to generic drug companies to boost their profit. For example, Teva, an Israel-based generic manufacturer recorded a 67% growth in 2010 as compared to previous year. These trends in pharma market pose a great challenge for innovative companies in terms of cost reduction in R&D and bringing new drugs to market. With dwindling R&D budget,... |
 |
| Featured Products |
|
 |
| Zetasizer Nano - Nanoparticle |
The system is available in a range of variants that allows you to select the best system for your application and budget, and the philosophy of the design
more» |
|
|
 |
| Indion Swift Demineralise |
Ion Exchange (India) Limited is famous for its widest range of Products – which help in Pretreatment, process water/liquid treatment, waste water treatment,...
more» |
|
|
 |
| Double Ended Autoclaves |
Often, double ended autoclaves may be considered a bespoke design, and although Priorclave has standard capacities up to 700litre, it is able to design and build to suit,...
more» |
|
  |
| Industry Updates |
|
|
|
| Events and Exhibition |
Drug Discovery Oxford 2012
Jan 5th - Jan 6th, 2012
University fo Oxford
Medical Sciences Training Centre
UK, SGC
drugdiscov2012@thesgc.org
|
|
|
 |
|
|
| Copyright © 2012. All rights reserved |
|
|
|
